Skip to main content
. 2011 Oct 31;5:333–342. doi: 10.4137/CMO.S7263

Table 2.

Discontinuation rates due to AEs.

Discontinuation due to adverse events (%) Pazopanib27 Sunitinib8,59 Sorafenib60 Axitinib57
Prior cytokine 19 11 NS 4*
Treatment naïve 12 19 11 NA

Note:

*

Includes prior anti-VEGF treatment.

Abbreviations: NS, Not stated; NA, Not available.